RIGL Stock — Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc (RIGL)

Updated October 16, 2026.

RIGL is a Stock. Total return is -92.8% over the past 25.9 years, 901.2 points behind SPY at 808.4%.

Rigel Pharmaceuticals is a biotechnology company that develops and commercializes therapies for hematologic disorders and cancer, including marketed drugs for chronic immune thrombocytopenia, acute myeloid leukemia, and RET fusion-positive cancers, along with pipeline candidates in earlier development stages. The company does not currently maintain an established distribution schedule. This security appeals to investors seeking exposure to biotechnology and oncology therapeutics rather than income-focused strategies.

RIGL performance versus SPY

Price and return data through 2026-10-16.

Total return is -92.8% over the past 25.9 years, 901.2 points behind SPY at 808.4%. Over the past year its total return — price change plus distributions reinvested — is 63.5%. Its deepest 1-year drawdown was 50.1%.

RIGL key facts

Asset type

Stock

Asset class

Equity

Inception date

11/29/2000

Distribution frequency

None

Last close

$45.97 (as of 2026-10-16)

Market cap

$858,713,348

Average volume

141431.0

Beta

1.187

Payout ratio

0.0%

P/E ratio

2.82

Forward P/E

9.2851

EPS

$16.30

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

RIGL risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 50.1%.

Who may consider RIGL — and who may not

It is a weaker fit for investors who need monthly cash flow (RIGL does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on RIGL

• All tickers starting with R

Tagged: Healthcare.

Frequently asked questions